20 completed, 5 terminated, 3 unknown, 1 enrolling by invitation. 8 Phase 4, 5 Phase 2, 4 Not applicable, 4 Phase 1, 4 Phase 3.
Follow Genital Herpes: new trials by email Literature Review of Genital Herpes trials Research Report on Genital Herpes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination Low-Dose Cohort, Mid-Dose Cohort, High-Dose Cohort - Genital Herpes | Phase 1 | Enrolling by invitation | Changchun BCHT Biotechnology Co. | 144 | 2025-10-13 | 2026-01-09 |
| A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes mRNA-1608, BEXSERO - Genital Herpes | Phase 1 / Phase 2 | Completed | ModernaTX, Inc. | 303 | 2023-09-06 | 2026-05-08 |
| A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 UB-621, Placebo - Genital Herpes | Phase 2 | Unknown | United BioPharma | 80 | 2023-06-01 | 2022-10-03 |
| Knowledge of Young Adults About Genital Herpes data collection - Genital Herpes | Unknown | Université de Reims Champagne-Ardenne | 2000 | 2022-12-02 | 2023-01-09 | |
| A Study of the Characteristics of Patients Diagnosed With Recurrent Symptomatic Genital Herpetic Disease Genital Herpes, Patient Engagement | Completed | Rational Vaccines Inc | 68 | 2022-08-03 | 2023-01-18 | |
| Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2 HSV 2 Formulation 1, HSV 2 Formulation 2, HSV 2 Formulation 3 - Genital Herpes | Phase 1 | Terminated | Sanofi Pasteur, a Sanofi Company | 24 | 2020-02-18 | 2022-10-25 |
| Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection GEN-003, Matrix-M2, 0.9% normal saline - Genital Herpes, HSV-2 Infection | Phase 2 | Terminated | Genocea Biosciences, Inc. | 33 | 2017-05-24 | 2019-02-19 |
| The VIBLOK SAfety and perFormancE Trial VIBLOK barrier cream - HSV-2 Infection, Genital Herpes | Not applicable | Completed | CLJI Worldwide | 82 | 2017-03-27 | 2020-02-13 |
| Melatonin Effects on Genital Herpes in Brazilian Women Melatonin 3 mg, Acyclovir - Genital Herpes | Phase 4 | Completed | University of Sao Paulo General Hospital | 90 | 2015-09-02 | 2022-01-11 |
| A Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital Herpes PEG-Formulation - Genital Herpes | Phase 2 | Terminated | Devirex AG | 8 | 2013-02-01 | 2014-08-05 |
| Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes AIC316, Valacyclovir - Genital Herpes | Phase 2 | Terminated | AiCuris Anti-infective Cures AG | 91 | 2012-10-01 | 2023-04-21 |
| Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes Famciclovir, Aciclovir - GENITAL HERPES | Phase 3 | Completed | EMS | 150 | 2012-07-01 | 2021-04-21 |
| Serologic Assays for the Diagnosis of Herpes Simplex Virus Type 2 Genital Herpes | Completed | Centers for Disease Control and Prevention | 2500 | 2009-07-01 | 2011-03-23 | |
| GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women acyclovir, matching placebo - Genital Herpes | Not applicable | Completed | University of Washington | 88 | 2009-01-01 | 2013-12-11 |
| Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2 valacyclovir, Valacyclovir - Genital Herpes | Phase 4 | Completed | University of Washington | 50 | 2008-11-01 | 2017-03-09 |
| A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation acyclovir - Genital Herpes | Phase 4 | Completed | University of Washington | 48 | 2008-08-01 | 2017-03-09 |
| Effect of HSV-2 Suppressive Therapy on Sexual Behavior acyclovir - Genital Herpes | Phase 4 | Terminated | University of Washington | 72 | 2008-01-01 | 2023-03-07 |
| Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIV valacyclovir, acyclovir - Genital Herpes, HIV Infection | Phase 4 | Completed | University of Washington | 28 | 2007-12-01 | 2018-06-07 |
| Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients Famciclovir, Placebo - Genital Herpes | Phase 4 | Completed | Novartis | 463 | 2007-06-01 | 2011-03-28 |
| HSV-2 Shedding Resolution After Acyclovir Treatment acyclovir - Genital Herpes | Completed | University of Washington | 36 | 2007-06-01 | 2012-03-22 |
Showing 20 of 29. Sign in to see all of them.
Herpes Genitalis (29) · Herpes Simplex (4) · HIV Infections (3) · Chlamydia Infections (2) · Gonorrhea (2) · Herpes Zoster (2) · Acquired Immunodeficiency Syndrome (1) · Hypersensitivity (1) · Papillomavirus Infections (1) · Patient Participation (1) · Sexual Behavior (1) · Sexually Transmitted Diseases (1) · Syphilis (1) · Vaginosis, Bacterial (1)
Communicable Diseases (29) · DNA Virus Infections (29) · Female Urogenital Diseases (29) · Female Urogenital Diseases and Pregnancy Complications (29) · Genital Diseases (29) · Genital Diseases, Female (29) · Genital Diseases, Male (29) · Herpesviridae Infections (29) · Infections (29) · Male Urogenital Diseases (29) · Sexually Transmitted Diseases, Viral (29) · Urogenital Diseases (29) · Virus Diseases (29) · Sexually Transmitted Diseases (28) · Herpes Simplex (25)
Acyclovir (8) · Valacyclovir (8) · Famciclovir (4) · 4CMenB vaccine (1) · Adjuvants, Pharmaceutic (1) · Circumcision, Male (1) · Cohort Studies (1) · Data Collection (1) · M2 protein, Influenza A virus (1) · Melatonin (1) · Saline Solution (1) · Sodium Chloride (1) · naphthalenesulfonic acid, polymer with formaldehyde (1) · pritelivir (1)
University of Washington (7) · Novartis (2) · Roxane Laboratories (2) · Agenus Inc. (1) · AiCuris Anti-infective Cures AG (1) · CLJI Worldwide (1) · Centers for Disease Control and Prevention (1) · Changchun BCHT Biotechnology Co. (1) · Devirex AG (1) · EMS (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · Genocea Biosciences, Inc. (1) · GlaxoSmithKline (1) · ModernaTX, Inc. (1) · Novartis Pharmaceuticals (1)
United States (17) · South Africa (3) · Brazil (2) · Uganda (2) · Zambia (2) · Australia (1) · Canada (1) · China (1) · France (1) · Germany (1) · Netherlands (1) · Switzerland (1) · Tanzania (1) · United Kingdom (1)
Anna Wald, MD, MPH (4) · Alan Copa, PharmD (2) · Christine Johnston, MD, MPH (2) · Christine Johnston, MD (1) · Connie Celum, MD, MPH (1) · Dalu Mohammed, Dr (1) · David Serwadda, MBChB,MPH (1) · Donna Felsenstein, MD (1) · Edmund C Baracat, PhD (1) · Godfrey Kigozi, MBChB, MPH (1) · Jared Baeten, MD, PhD (1) · Rajul Patel (1)
PMID 22225814, PMID 18532873, PMID 19192993, PMID 19220138, PMID 19321868, PMID 19389002, PMID 19616720, PMID 19936044, PMID 20070143, PMID 20370481, PMID 21216000, PMID 21489882, PMID 22183840, PMID 27997653
K23AI071257 (1), P01AI030731 (1), R01AI050132 (1), U01AI052054 (1), U19AI031448 (1)